Tirzepatide
🔬 Overview
Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. As a prescription medicine it is used for type 2 diabetes and weight management. Sold as a research chemical it comes as lyophilised powder.
Like semaglutide, it is dosed weekly and titrated slowly. It sits between single agonists and the triple agonist retatrutide in mechanism.
💉 Research-Reported Dosing
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Research start | 2.5 mg | Once weekly | First 4 weeks |
| Step 2 | 5 mg | Once weekly | After 4 weeks |
| Titration | 7.5-10 mg | Once weekly | Gradual escalation |
| Upper range | 12.5-15 mg | Once weekly | Slow steps only |
Figures are drawn from research literature and community protocols. They are not dosing recommendations. Use the dosage calculator to convert any amount into a syringe volume.
⚗️ Reconstitution & Solubility
- Bring vial and bacteriostatic water to room temperature
- Swab stoppers and let dry
- Add bacteriostatic water gently down the vial wall
- Swirl until clear, do not shake
- Store refrigerated at 2 to 8 C
📍 Administration
Subcutaneous injection once weekly in research settings, with slow titration to manage gastrointestinal effects. Convert doses with the calculator.
📚 Research Notes
Clinical data for the approved drug is substantial. Gastrointestinal effects are the most commonly reported, strongest after each dose increase and easing over time.
⚠️ Safety & Disclaimer
Tirzepatide is a prescription-only medicine. Research-chemical powder is not for human use and is not equivalent to prescribed product. Known risks include gastrointestinal effects, gallbladder issues, pancreatitis signals, and a class warning on thyroid C-cell tumours. Not medical advice. Human use only under medical supervision.